Is NCT07300150 recruiting in Fairfax, VA?

Yes, NCT07300150 is currently recruiting participants at its Fairfax, VA location. This colorectal cancer clinical trial is actively enrolling qualified participants.

How do I join the colorectal cancer clinical trial in Fairfax?

To join this clinical trial in Fairfax, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Fairfax clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Colorectal Cancer Clinical Trial in Fairfax, VA

About This Colorectal Cancer Study in Fairfax

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Sponsor: PAQ Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Men or women less than or equal to (\>=) 18 years of age

Histologically or cytologically confirmed advanced or metastatic solid malignancy

Participant has a pathologically documented, locally advanced or metastatic malignancy with any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing using a Clinical Laboratory Improvement Amendments (CLIA) certified, validated institutional or commercial test

Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available therapies known to provide clinical benefit

Measurable disease (RECIST 1.1 Criteria)

ECOG Performance Status 0 or 1

Willingness to avoid pregnancy or fathering children screening through 90 days after the last dose of study treatment

Exclusion Criteria

Cancer History

Active brain metastasis or carcinomatous meningitis. If participants have had brain metastases resected or have received radiation therapy, they may be eligible if: (1) study treatment begins at least 4 weeks from the end of brain-specific therapy, (2) residual neurological symptoms Grade \<=2, (3) currently on stable doses of corticosteroids, and (4) pre-study brain MRI documents no new/worsening brain lesions

History of any other malignancy within the past 2 years, except:

Malignancy treated with curative intent and with no known active disease present \>=2 years before enrolment and felt to be at low risk for recurrence by the investigator

Basal or squamous cell carcinoma of the skin, in situ cervical cancer, early -stage endometrial cancer that has been definitively treated, superficial bladder cancer, Gleason 6/7 treated prostate cancer, and ductal carcinoma in situ or lobular carcinoma in situ of the breast Prior Cancer Therapy

Unresolved toxicities from prior anti-cancer therapies. Participants with prior endocrine replacement therapies are eligible for entry even if administered to treat endocrine deficiency due to the prior anti-cancer therapy

Concurrent participation in another interventional clinical study.

Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of study drug:

At least 14 days for chemotherapy or targeted small-molecule therapy

At least 28 days for a prior monoclonal antibody

At least 28 days or 5 half-lives (whichever is longer) for all other investigational study drugs or devices. For drugs with very long half-lives, participants may be allowed to enroll prior to 5 half-lives at the discretion of the investigator in discussion with the medical monitor

Note: Concurrent hormonal therapy for prostate or breast cancer is allowable

Prior treatment with a KRAS/RAS degrader Medical History

Significant cardiovascular disease within 6 months of starting study therapy

Active infection requiring antibiotics within 7 days of study treatment.

Known HIV infection with a CD4+ T-cell count \<200 cells/mcL and/or a detectable viral load per parameters of assay and/or on an anti-retroviral regimen containing a strong or moderate CYP3A4/5 inhibitor or inducer and/or on a new anti-retroviral regimen for less than 28 days prior to the initiation of study treatment

Known history of drug-induced liver injury; primary biliary cirrhosis; or ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension

Major surgery within 4 weeks of the start of study therapy or postoperative complications preventing the participant from adhering to protocol assessments and procedures

Known hypersensitivity to any of the products to be administered during dosing

Any disease or disorder that, in the opinion of the investigator, may compromise the ability of the participant to provide written informed consent and/or to comply with all required study procedures Medications • Part 1a (Dose escalation): Use of a strong or moderate CYP3A4/5 inhibitor or inducer, Use of a strong P-gp inhibitor or inducer Organ Function • Participants with laboratory values indicating inadequate hematology, hepatic, or renal function Diagnostic Assessments

Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG

Baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) \>=470 msec

Female participants of childbearing age with a positive urine or serum test within 7 days of study start or confirmation from Ob/Gyn that any positive bHCG test is not representative of an ongoing pregnancy

Women who are lactating/breast feeding or who plan to breastfeed while on study through 28 days after receiving the last dose of study drug

Active HBV infection. Participants with resolved infection or who are on Stable antiviral therapy are eligible

Active HCV infection. Participants who have completed definitive antiviral therapy with post treatment confirmation of eradication are eligible

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT07300150) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Treatment Options in Fairfax, VA

If you're searching for colorectal cancer treatment options in Fairfax, VA, this clinical trial (NCT07300150) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer clinical trials near you to find additional studies recruiting in your area.

Colorectal Cancer Clinical Trial in Fairfax, VA

Expert Care in Fairfax

IRB Approved

No-Cost Care

Apply for This Fairfax Location

Why Participate?

Simple Process